International Journal of STD & AIDS最新文献_第2页

Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention. 了解每月使用达匹韦林阴道环预防 HIV-1 试验中疗效稀释的来源。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-03-01 Epub Date: 2024-11-26 DOI: 10.1177/09564624241300199

Kathryn Peebles, Laura Matrajt, Jared M Baeten, Thesla Palanee-Phillips, Elizabeth R Brown

{"title":"Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention.","authors":"Kathryn Peebles, Laura Matrajt, Jared M Baeten, Thesla Palanee-Phillips, Elizabeth R Brown","doi":"10.1177/09564624241300199","DOIUrl":"10.1177/09564624241300199","url":null,"abstract":"Introduction: Women-initiated HIV - 1 prevention products are key to reducing women's HIV-1 risk. Clinical trials of vaginal microbicides have shown limited to no efficacy in intention-to-treat (ITT) analyses. It is hypothesized that these negative results are partly due to efficacy dilution.Methods: We developed a microsimulation model of MTN-020/ASPIRE, a phase 3 trial that evaluated monthly use of a dapivirine vaginal ring for HIV-1 prevention. We evaluated four sources of efficacy dilution: trial-level factors: (i) an imbalance in the number of monthly sex acts between study arms and (ii) heterogeneity in risk emergent over time; and individual-level factors: (iii) product non-adherence and (iv) receptive anal intercourse.Results: Assuming 70% per-vaginal exposure efficacy (consistent with the ITT estimate of 27%), heterogeneity in risk accounted for the largest proportion of efficacy dilution, at 42% (90% CrI: 38, 45), followed by non-adherence (33%; 90% CrI: 27, 39), an imbalance in arms (18%; 90% CrI: 16, 21) and lastly, anal intercourse with less than 10% of efficacy dilution.Conclusion: Our results suggest that heterogeneity in risk was the most important source of efficacy dilution in the ASPIRE trial. Future trials of HIV-1 prevention products for women should consider alternative trial designs and analytic approaches that minimize bias introduced by heterogeneity in risk.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"195-204"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Barriers to HIV pre-exposure prophylaxis uptake for men who have sex with both men and women: A global scoping review.

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-18 DOI: 10.1177/09564624251321564

Jodie Crossman, Daniel Richardson

{"title":"Barriers to HIV pre-exposure prophylaxis uptake for men who have sex with both men and women: A global scoping review.","authors":"Jodie Crossman, Daniel Richardson","doi":"10.1177/09564624251321564","DOIUrl":"https://doi.org/10.1177/09564624251321564","url":null,"abstract":"Background: Although PrEP is a highly effective HIV prevention method, some groups are underrepresented in PrEP uptake. Much HIV prevention research groups gay, bisexual and other men who have sex with men together; however, men who have sex with both men and women (MSWM) may have needs distinct from those who identify as exclusively gay. This scoping review aims to explore documented barriers to PrEP use among MSWM.Methods: Literature was searched using four databases. Studies were included if data referring to MSWM were reported as a distinct category. Data were extracted using a standardised form, and findings were stratified into relevant categories of the social ecological framework.Results: Alongside intersectional barriers, MSWM were found to have lower awareness of PrEP, and access sexual health services less than men who have sex only with men. Those who did not identify with the LGBT community often missed out on health promotion messages for this group and were less likely to be offered HIV prevention interventions. MSWM identified more stigmatisation around PrEP use than gay men. However, when aware of PrEP, MSWM were very motivated to use this intervention.Conclusions: Not all MSM will identify within the LGBTQ + community and may miss out on valuable opportunities for HIV prevention. PrEP information should be widely available in a variety of health and community settings. Health care professionals should avoid assumptions when assessing patients and provide information about HIV and STI prevention to all attending sexual health services.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624251321564"},"PeriodicalIF":1.4,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to "Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort".

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-16 DOI: 10.1177/09564624251320827

引用次数: 0

Granulomatous vulvitis complicated by polymicrobial growth. 肉芽肿性外阴炎并发多微生物生长。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-05 DOI: 10.1177/09564624251318086

Divya Madonna Dsouza, Jacintha Martis, Rochelle Cheryl Monteiro, Jyothi Jayaraman, Prajna Shetty

引用次数: 0

Increasing new cases of mpox in Italy: From an epidemic infection to an endemic sexually transmitted disease? 意大利水痘新病例不断增加：从流行性传染病到地方性传染病？

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-04 DOI: 10.1177/09564624251318444

Gionathan Orioni, Bianca Maria Piraccini, Valeria Gaspari

引用次数: 0

Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis.

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-03 DOI: 10.1177/09564624251315781

Tanvi Vaidya, Monisha Madhumita

{"title":"Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis.","authors":"Tanvi Vaidya, Monisha Madhumita","doi":"10.1177/09564624251315781","DOIUrl":"https://doi.org/10.1177/09564624251315781","url":null,"abstract":"Tofacitinib is a Janus kinase 3 (JAK3) inhibitor effective in treating alopecia areata (AA) by promoting hair regrowth. Its mechanism may involve upregulation of vascular endothelial growth factor (VEGF) and reduction of inflammation. However, the range of effects, particularly on hair growth in specific populations, remains under-investigated. We describe a patient with HIV, well-controlled on antiretroviral therapy, who developed hirsutism after starting tofacitinib for AA. This unexpected side effect of hypertrichosis was completely resolved after discontinuing the medication and undergoing a single session of laser hair removal (LHR). This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. The case emphasizes the need for careful monitoring of hair growth and other potential side effects in patients on tofacitinib, especially those with underlying immune-modulating conditions. It also suggests that LHR can be an effective treatment for medication-induced hirsutism.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624251315781"},"PeriodicalIF":1.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genital-oral transmission of Candida lusitaniae. 卢西塔尼亚念珠菌的生殖器-口腔传播。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-01 Epub Date: 2024-10-29 DOI: 10.1177/09564624241296582

Stefano Veraldi, Paolo Bortoluzzi, Francesca Germiniasi, Anna Grancini

引用次数: 0

HIV retesting among people living with HIV in Lesotho in 2022. 2022 年莱索托艾滋病毒感染者的艾滋病毒再检测。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-01 Epub Date: 2024-10-22 DOI: 10.1177/09564624241289984

Spencer D Pogue, Suzue Saito, Mphotleng Tlhomola, Christine A West, Fred Asiimwe, Puleng Ramphalla, Eugenie Poirot, Claire Steiner, Abigail R Greenleaf

{"title":"HIV retesting among people living with HIV in Lesotho in 2022.","authors":"Spencer D Pogue, Suzue Saito, Mphotleng Tlhomola, Christine A West, Fred Asiimwe, Puleng Ramphalla, Eugenie Poirot, Claire Steiner, Abigail R Greenleaf","doi":"10.1177/09564624241289984","DOIUrl":"10.1177/09564624241289984","url":null,"abstract":"Background: Despite widespread HIV testing in sub-Saharan Africa, regular testing among at-risk populations is crucial for effective prevention. However, reports increasingly indicate retesting among people living with HIV (PLHIV), a group that would not require additional testing since they would already have received a confirmed diagnosis. We describe the demographic characteristics of PLHIV retesters in Lesotho, report the average number of HIV tests post-diagnosis among PLHIV, and share motivations for retesting.Methods: In August 2022, a nationally representative cohort in Lesotho participated in a cell phone survey about their HIV status and testing history. Study participants were recruited from a face-to-face survey conducted in 2020, Lesotho Population Based HIV Impact Assessment survey.Results: Of the 1523 participants called, 1111 participants responded (72.9%) and 266 reported living with HIV. We found 18.8% of people living with HIV (PLHIV) reported retesting at least once for HIV, and 58% of PLHIV who reported retesting were likely or very likely to retest for HIV in the coming year. The main reason PLHIV reported retesting was because a health care worker offered the test (61.7%) followed by self-initiated testing to confirm their status (29.1%). Among male PLHIV who had a history of retesting, 92.0% were very likely or likely to retest, compared to only 30.6% of female PLHIV.Conclusion: We found almost a fifth of PLHIV in Lesotho reported a history of retesting for HIV, and 58% of PLHIV were likely or very likely to retest for HIV in the coming year. Educating providers and men living with HIV could reduce retesting among PLHIV.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"114-118"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Electronic Health interventions for HIV in Pakistan: Is it the only way out? 巴基斯坦艾滋病电子健康干预：这是唯一的出路吗？

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-01 Epub Date: 2024-11-09 DOI: 10.1177/09564624241299570

Muhammad Atique, Muhammad Abbas Abid

引用次数: 0

Effective management of multidrug-resistant HIV with lenacapavir and fostemsavir: A case study. 来那卡韦和福斯替沙韦对耐多药艾滋病病毒的有效管理：案例研究。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2025-02-01 Epub Date: 2024-11-01 DOI: 10.1177/09564624241296583

Francisca Bartilotti Matos, Dara Mbanze, Perpétua Gomes, Cristóvão Figueiredo, Daniel Coutinho, Sofia Nunes, Carlos Azevedo, Joana Fragoso, Tiago Teixeira, Luís Malheiro

引用次数: 0